Entity

Time filter

Source Type

Mansfeld, Germany

Rothman N.,U.S. National Cancer Institute | Garcia-Closas M.,U.S. National Cancer Institute | Chatterjee N.,U.S. National Cancer Institute | Malats N.,Spanish National Cancer Research Center | And 114 more authors.
Nature Genetics | Year: 2010

We conducted a multi-stage, genome-wide aSociation study of blaDer cancer with a primary scan of 591,637 SNPs in 3,532 affected individuals (cases) and 5,120 controls of European descent from five studies foLowed by a replication strategy, which included 8,382 cases and 48,275 controls from 16 studies. In a combined analysis, we identified thrE new regions aSociated with blaDer cancer on chromosomes 22q13.1, 19q12 and 2q37.1: rs1014971, (P = 8-10-12) maps to a non-genic region of chromosome 22q13.1, rs8102137 (P = 2-10-11) on 19q12 maps to CNE1 and rs11892031 (P = 1-10-7) maps to the UGT1A cluster on 2q37.1. We confirmed four previously identified genome-wide aSociations on chromosomes 3q28, 4p16.3, 8q24.21 and 8q24.3, validated previous candidate aSociations for the GSTM1 deletion (P = 4-10-11) and a tag SNP for NAT2 acetylation status (P = 4-10-11), and found interactions with smoking in both regions. Our findings on coMon variants aSociated with blaDer cancer risk should provide new insights into the mechanisms of carcinogenesis. © 2010 Nature America, Inc. All rights reserved. Source


Selinski S.,Leibniz Research Center for Working Environment and Human Factors o | Lehmann M.-L.,Leibniz Research Center for Working Environment and Human Factors o | Blaszkewicz M.,Leibniz Research Center for Working Environment and Human Factors o | Ovsiannikov D.,St. Josefs Hospital | And 37 more authors.
Archives of Toxicology | Year: 2012

Currently, twelve validated genetic variants have been identified that are associated with urinary bladder cancer (UBC) risk. However, those validated variants explain only 5-10% of the overall inherited risk. In addition, there are more than 100 published polymorphisms still awaiting validation or disproval. A particularly promising of the latter unconfirmed polymorphisms is rs2854744 that recently has been published to be associated with UBC risk. The [A] allele of rs2854744 has been reported to be associated with a higher promoter activity of the insulin-like growth factor-binding protein-3 (IGFBP3) gene, which may lead to increased IGFBP-3 plasma levels and cancer risk. Therefore, we investigated the association of rs2854744 with UBC in the IfADo case-control series consisting of 1,450 cases and 1,725 controls from Germany, Hungary, Venezuela and Pakistan. No significant association of rs2854744 with UBC risk was obtained (all study groups combined: unadjusted P = 0.4446; adjusted for age, gender and smoking habits P = 0.6510), besides a small effect of the [A] allele in the Pakistani study group opposed to the original findings (unadjusted P = 0.0508, odds ratio (OR) = 1.43 for the multiplicative model) that diminished after adjustment for age, gender and smoking habits (P = 0.7871; OR = 0.93). Associations of rs2854744 with occupational exposure to urinary bladder carcinogens and smoking habits were also not present. A meta-analysis of all available case-control series including the original discovery study resulted in an OR of 1.00 (P = 0.9562). In conclusion, we could not confirm the recently published hypothesis that rs2854744 in the IGFBP3 gene is associated with UBC risk. © 2011 Springer-Verlag. Source


Selinski S.,Leibniz Research Center for Working Environment and Human Factors o | Lehmann M.-L.,Leibniz Research Center for Working Environment and Human Factors o | Blaszkewicz M.,Leibniz Research Center for Working Environment and Human Factors o | Ovsiannikov D.,St. Josefs Hospital | And 36 more authors.
Archives of Toxicology | Year: 2012

Recently, rs11892031[A] has been identified in a genome-wide association study (GWAS) to confer increased risk of urinary bladder cancer (UBC). To confirm this association and additionally study a possible relevance of exposure to urinary bladder carcinogens, we investigated the IfADo UBC study group, consisting of eight case-control series from different regions including 1,805 cases and 2,141 controls. This analysis was supplemented by a meta-analysis of all published data, including 13,395 cases and 54,876 controls. Rs11892031 A/A was significantly associated with UBC risk in the IfADocase-control series adjusted to cigarette smoking, gender, age and ethnicity (OR = 1.18; 95% CI = 1.02-1.37; P = 0.026). In the meta-analysis, a convincing association with UBC risk was obtained (OR = 1.19; 95% Cl = 1.12-1.26; P < 0.0001). Interestingly, the highest odds ratios were obtained for individual case-control series with a high degree of occupational exposure to polycyclic aromatic hydrocarbons and aromatic amines: cases with suspected occupational UBC (OR = 1.41) and cases from the highly industrialized Ruhr area (OR = 1.98) compared with Ruhr area controls (all combined OR = 1.46). Odds ratios were lower for study groups with no or a lower degree of occupational exposure to bladder carcinogens, such as the Hungary (OR = 1.02) or the ongoing West German case-control series (OR = 1.06). However, the possible association of rs11892031[A] with exposure to bladder carcinogens still should be interpreted with caution, because in contrast to the diVerences between the individual study groups, interview- based data on occupational exposure were not significantly associated with rs11892031. In conclusion, the association of rs11892031[A] with UBC risk could be confirmed in independent study groups. © Springer-Verlag 2012. Source


Selinski S.,Leibniz Research Center for Working Environment and Human Factors o | Blaszkewicz M.,Leibniz Research Center for Working Environment and Human Factors o | Lehmann M.-L.,Leibniz Research Center for Working Environment and Human Factors o | Ovsiannikov D.,St Josefs Hospital Dortmund Hoerde | And 38 more authors.
Pharmacogenetics and Genomics | Year: 2011

Genotyping N-acetyltransferase 2 (NAT2) is of high relevance for individualized dosing of antituberculosis drugs and bladder cancer epidemiology. In this study we compared a recently published tagging single nucleotide polymorphism (SNP) (rs1495741) to the conventional 7-SNP genotype (G191A, C282T, T341C, C481T, G590A, A803G and G857A haplotype pairs) and systematically analysed if novel SNP combinations outperform the latter. For this purpose, we studied 3177 individuals by PCR and phenotyped 344 individuals by the caffeine test. Although the tagSNP and the 7-SNP genotype showed a high degree of correlation (R=0.933, P<0.0001) the 7-SNP genotype nevertheless outperformed the tagging SNP with respect to specificity (1.0 vs. 0.9444, P=0.0065). Considering all possible SNP combinations in a receiver operating characteristic analysis we identified a 2-SNP genotype (C282T, T341C) that outperformed the tagging SNP and was equivalent to the 7-SNP genotype. The 2-SNP genotype predicted the correct phenotype with a sensitivity of 0.8643 and a specificity of 1.0. In addition, it predicted the 7-SNP genotype with sensitivity and specificity of 0.9993 and 0.9880, respectively. The prediction of the NAT2 genotype by the 2-SNP genotype performed similar in populations of Caucasian, Venezuelan and Pakistani background. A 2-SNP genotype predicts NAT2 phenotypes with similar sensitivity and specificity as the conventional 7-SNP genotype. This procedure represents a facilitation in individualized dosing of NAT2 substrates without losing sensitivity or specificity. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins. Source


Kiemeney L.A.,Biostatistics and Health Technology Assessment | Kiemeney L.A.,Radboud University Nijmegen | Kiemeney L.A.,Comprehensive Cancer Center East | Sulem P.,DeCODE Genetics Inc. | And 80 more authors.
Nature Genetics | Year: 2010

Previously, we reported germline DNA variants associated with risk of urinary bladder cancer (UBC) in Dutch and Icelandic subjects. Here we expanded the Icelandic sample set and tested the top 20 markers from the combined analysis in several European case-control sample sets, with a total of 4,739 cases and 45,549 controls. The T allele of rs798766 on 4p16.3 was found to associate with UBC (odds ratio = 1.24, P = 9.9 × 10 12). rs798766 is located in an intron of TACC3, 70 kb from FGFR3, which often harbors activating somatic mutations in low-grade, noninvasive UBC. Notably, rs798766[T] shows stronger association with low-grade and low-stage UBC than with more aggressive forms of the disease and is associated with higher risk of recurrence in low-grade stage Ta tumors. The frequency of rs798766[T] is higher in Ta tumors that carry an activating mutation in FGFR3 than in Ta tumors with wild-type FGFR3. Our results show a link between germline variants, somatic mutations of FGFR3 and risk of UBC. © 2010 Nature America, Inc. All rights reserved. Source

Discover hidden collaborations